Insider Trading (SEC Form 4)


Insiders are officers, directors, or significant investors. This page shows recent insider transactions for Biological.

Transaction
Date
CompanyInsider Code
(see below)
Shares Post Shares Percent
Change
Share
Price
Tran
Value
Post
Value
Percent
Change
2019-12-29 LPTN H.I.G. Ventures - Endosurgery, LLC (10% Owner) J 1,451,185 1,451,185
2019-12-29 LPTN Remeditex Ventures LLC (10% Owner) J 1,309,392 1,309,392
2018-01-17 JUNO Azelby Robert (EVP & Chief Commercial Officer) M 2,498 73,330 3.53 25.29 63,174
2018-01-17 JUNO Azelby Robert (EVP & Chief Commercial Officer) M 26,633 99,963 36.32 20.76 552,901
2018-01-17 JUNO Azelby Robert (EVP & Chief Commercial Officer) S -21,141 78,822 -21.15 68.10 -1,439,702 5,367,778 -26.82
2018-01-17 JUNO Azelby Robert (EVP & Chief Commercial Officer) S -7,990 70,832 -10.14 69.95 -558,900 4,954,698 -11.28
2018-01-17 GNCA Clark William D (President and CEO, Director) P 25,000 82,931 43.15 0.80 20,000 66,345 30.15
2018-01-17 IDRA Pillar Invest Corp (10% Owner) Pillar Pharmaceuticals III, L.P. (10% Owner) S -200,000 0 -100.00 2.40 -480,000
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) M 5,000 5,000 18.17 90,850
2018-01-16 GILD Meyers James R (EVP Worldwide Commercial Ops) M 100,000 102,715 3,683.24 21.575 2,157,500
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) M 245,750 2,772,679 9.73 6.36 1,562,970
2018-01-16 PRTO NOYES TIMOTHY P (President and CEO, Director) D -10,000 8,742 -53.36 2.357 -23,570
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) S -42,457 2,502,429 -1.67 48.5648 -2,061,916 121,529,964 -1.70
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) S -23,003 2,544,886 -0.90 47.6925 -1,097,071 121,371,976 -0.90
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) S -65,820 2,706,859 -2.37 44.7163 -2,943,227 121,040,719 -2.43
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) S -49,082 2,567,889 -1.88 46.5247 -2,283,525 119,470,265 -1.91
2018-01-16 JUNO Bishop Hans Edgar (CEO & President, Director) S -89,888 2,616,971 -3.32 45.5321 -4,092,789 119,156,185 -3.43
2018-01-16 ATRA Ciechanover Isaac E. (Chief Executive Officer, Director) S -600 1,103,153 -0.05 30.38 -18,228 33,513,788 -0.05
2018-01-16 NBIX GORMAN KEVIN CHARLES (Chief Executive Officer, Director) S -3,750 336,357 -1.10 78.8853 -295,820 26,533,623 -1.11
2018-01-16 NBIX Bozigian Haig P. (Chief Development Officer) S -1,625 131,226 -1.22 79.1229 -128,575 10,382,982 -1.24
2018-01-16 AMGN Harper Sean E (EVP, Research & Development) S -1,525 54,673 -2.71 185.62 -283,070 10,148,402 -2.79
2018-01-16 NBIX Grigoriadis Dimitri E. (Chief Research Officer) S -1,625 79,316 -2.01 79.1157 -128,563 6,275,141 -2.05
2018-01-16 NBIX Gano Kyle (Chief Business Development Off) S -1,625 74,871 -2.12 79.052 -128,460 5,918,702 -2.17
2018-01-16 NBIX OBrien Christopher Flint (Chief Medical Officer) S -1,750 50,723 -3.34 79.1423 -138,499 4,014,335 -3.45
2018-01-16 RGNX Vasista Vittal (Chief Financial Officer) S -5,000 107,283 -4.45 30.16 -150,800 3,235,655 -4.66
2018-01-16 GILD Meyers James R (EVP Worldwide Commercial Ops) S -75,157 27,558 -73.17 79.9961 -6,012,267 2,204,533 -272.72
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -496 4,504 -9.92 101.99 -50,587 459,363 -11.01
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -464 4,040 -10.30 103.56 -48,052 418,382 -11.49
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -1,074 2,966 -26.58 104.64 -112,383 310,362 -36.21
2018-01-16 CVM TALOR EYAL (CSO) S -1,707 119,449 -1.41 2.15 -3,670 256,815 -1.43
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -624 2,342 -21.04 105.89 -66,075 247,994 -26.64
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -84 2,258 -3.59 106.49 -8,945 240,454 -3.72
2018-01-16 GILD Meyers James R (EVP Worldwide Commercial Ops) S -24,843 2,715 -90.15 80.9925 -2,012,097 219,895 -915.03
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -1,019 1,239 -45.13 108.14 -110,195 133,985 -82.24
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -963 276 -77.72 109.75 -105,689 30,291 -348.91
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -100 176 -36.23 110.30 -11,030 19,413 -56.82
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -126 50 -71.59 111.41 -14,038 5,570 -252.00
2018-01-16 AVXS LITALIEN JAMES J (SrVP/Chief Reg&Quality Officer) S -50 0 -100.00 112.50 -5,625
2018-01-12 ATRA MCGRATH JOHN (EVP & Chief Financial Officer) M 30,000 123,154 32.20 11.00 330,000
2018-01-12 XLRN Rovaldi Christopher (SVP, Program Mgmt and Ops) M 11,000 35,701 44.53 24.11 265,210
2018-01-12 ATRA Ciechanover Isaac E. (Chief Executive Officer, Director) S -100 1,103,753 -0.01 30.05 -3,005 33,167,778 -0.01
2018-01-12 ATRA MCGRATH JOHN (EVP & Chief Financial Officer) S -3,500 119,654 -2.84 22.32 -78,120 2,670,677 -2.93
2018-01-12 ATRA MCGRATH JOHN (EVP & Chief Financial Officer) S -30,000 89,654 -25.07 25.00 -750,000 2,241,350 -33.46
2018-01-12 XLRN Rovaldi Christopher (SVP, Program Mgmt and Ops) S -11,000 24,701 -30.81 45 -495,000 1,111,545 -44.53
2018-01-12 CVM TALOR EYAL (CSO) S -101 121,156 -0.08 2.15 -217 260,485 -0.08
2018-01-11 RGNX Mills Kenneth T. (President and CEO, Director) M 150,000 258,530 138.21 0.85 127,500
2018-01-11 GILD Alton Gregg H (EVP Comm&Acs ALA, Corp&Med Aff) M 7,501 57,114 15.12 24.905 186,812
2018-01-11 GILD Alton Gregg H (EVP Comm&Acs ALA, Corp&Med Aff) M 18,374 75,488 32.17 40.56 745,249
2018-01-11 SGEN SIEGALL CLAY B (President and CEO, Director) M 10,570 697,716 1.54 11.09 117,221
2018-01-11 SGEN SIEGALL CLAY B (President and CEO, Director) M 7,562 694,708 1.10 11.09 83,863
A
Grant, award, or other acquisition of securities from the company (such as an option)
K
Equity swaps and similar hedging transactions
P
Purchase of securities on an exchange or from another person
S
Sale of securities on an exchange or to another person
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
M
Exercise or conversion of derivative security received from the company (such as an option)
G
Gift of securities by or to the insider
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)